Tositumomab and iodine I 131 tositumomab (The BEXXAR (R) therapeutic regimen) produced ongoing, durable remissions of more than 5 years in 9 patients with non-Hodgkin's lymphoma (NHL) in a pivotal study of patients refractory to their last chemotherapy Meeting Abstract
| Authors: | Kaminski, M. S.; Zelenetz, A. D.; Press, O. W.; Saleh, M. N.; Leonard, J. P.; Fehrenbacher, L.; Lister, T. A.; Kroll, S.; Wahl, R. L.; Knox, S. J.; Vose, J. M. |
| Abstract Title: | Tositumomab and iodine I 131 tositumomab (The BEXXAR (R) therapeutic regimen) produced ongoing, durable remissions of more than 5 years in 9 patients with non-Hodgkin's lymphoma (NHL) in a pivotal study of patients refractory to their last chemotherapy |
| Meeting Title: | 46th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 104 |
| Issue: | 11 Pt. 1 |
| Meeting Dates: | 2004 Dec 4-7 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2004-11-16 |
| Start Page: | 720A |
| Language: | English |
| ACCESSION: | WOS:000225127502632 |
| PROVIDER: | wos |
| PUBMED: | 15562524 |
| DOI: | 10.1182/blood.V104.11.2631.2631 |
| Notes: | Meeting Abstract: 2631 -- 46th Annual Meeting of the American-Society-of-Hematology -- DEC 04-07, 2004 -- San Diego, CA -- 1 -- Source: Wos |
